Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Enlivex Therapeutics Ltd (ENLV)

Enlivex Therapeutics Ltd (ENLV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 94,805
  • Shares Outstanding, K 18,373
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,470 K
  • 60-Month Beta 1.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.20
Trade ENLV with:

Options Overview Details

View History
  • Implied Volatility 138.18% ( -27.68%)
  • Historical Volatility 74.78%
  • IV Percentile 68%
  • IV Rank 22.38%
  • IV High 291.07% on 07/29/22
  • IV Low 94.10% on 01/21/22
  • Put/Call Vol Ratio 0.03
  • Today's Volume 69
  • Volume Avg (30-Day) 570
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 8,203
  • Open Int (30-Day) 4,706

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.45
  • Number of Estimates 1
  • High Estimate -0.45
  • Low Estimate -0.45
  • Prior Year -0.17
  • Growth Rate Est. (year over year) -164.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.03 +28.04%
on 07/26/22
5.68 -9.15%
on 07/08/22
+0.60 (+13.16%)
since 07/05/22
3-Month
3.77 +36.87%
on 05/18/22
5.68 -9.15%
on 07/08/22
+1.35 (+35.43%)
since 05/05/22
52-Week
3.65 +41.37%
on 05/05/22
13.95 -63.01%
on 08/31/21
-3.14 (-37.83%)
since 08/05/21

Most Recent Stories

More News
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™

Nes-Ziona, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming...

ENLV : 5.16 (+1.78%)
Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

First clinical trial of Allocetra™ in patients with cancer builds upon promising preclinical studies demonstrating its broadly applicable immunotherapeutic...

ENLV : 5.16 (+1.78%)
Enlivex to Present at the 2022 Jefferies Healthcare Conference

Nes-Ziona, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage macrophage reprogramming immunotherapy...

ENLV : 5.16 (+1.78%)
Enlivex Announces Upcoming May Conference Presentations

Nes-Ziona, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming...

ENLV : 5.16 (+1.78%)
Enlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting

Mesothelioma is one of the deadliest solid cancers, with few treatment options, all of which have limited efficacy. Immune checkpoint inhibitors targeting...

ENLV : 5.16 (+1.78%)
Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra

Nes-Ziona, Israel, May 05, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming...

ENLV : 5.16 (+1.78%)
Enlivex Announces Full Year 2021 Financial Results, Completion of Development of Frozen Formulation Allocetra™ Ahead of Schedule, and Provides Strategic & Business Updates

Development of frozen formulation Allocetra™, a primary cornerstone of Enlivex’s R&D efforts during the last two years, was successfully completed in...

ENLV : 5.16 (+1.78%)
BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study

BioCardia (BCDA) gets FDA approval to start a phase I/II study to evaluate its allogenic stem cell therapy candidate, BCDA-04, in patients with ARDS due to COVID-19.

NVS : 85.57 (+0.40%)
MESO : 3.49 (+9.06%)
BCDA : 1.4500 (+0.69%)
ENLV : 5.16 (+1.78%)
Enlivex CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer–BioNTech COVID-19 Vaccine in The New England Journal of Medicine

Publication follows the Israeli Ministry of Health’s appointment of Prof. Mevorach as the lead investigator of a team evaluating side effects of COVID-19...

ENLV : 5.16 (+1.78%)
Acer's (ACER) NDA for ACER-001 in UCD Gets FDA Acceptance

The FDA accepts Acer's (ACER) NDA for ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders. A decision is due on Jun 5, 2022. Stock up.

HZNP : 69.60 (+3.88%)
ATXI : 0.2733 (+0.22%)
ACER : 1.4400 (+0.70%)
ENLV : 5.16 (+1.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome)...

See More

Key Turning Points

3rd Resistance Point 5.60
2nd Resistance Point 5.47
1st Resistance Point 5.31
Last Price 5.16
1st Support Level 5.02
2nd Support Level 4.89
3rd Support Level 4.73

See More

52-Week High 13.95
Fibonacci 61.8% 10.02
Fibonacci 50% 8.80
Fibonacci 38.2% 7.58
Last Price 5.16
52-Week Low 3.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar